Cecilia Boz
A5037351267- COVID-19 Clinical Research Studies
- Galectins and Cancer Biology
- SARS-CoV-2 and COVID-19 Research
- Computational Drug Discovery Methods
- Biomarkers in Disease Mechanisms
- Peptidase Inhibition and Analysis
- Pharmacological Receptor Mechanisms and Effects
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Toxin Mechanisms and Immunotoxins
- Antibiotics Pharmacokinetics and Efficacy
- Amoebic Infections and Treatments
- Pancreatitis Pathology and Treatment
- Macrophage Migration Inhibitory Factor
- Occupational and environmental lung diseases
- Chronic Obstructive Pulmonary Disease (COPD) Research
Queen's Medical Centre
2021-2022
Centre for Inflammation Research
2021-2022
University of Edinburgh
2021-2022
The Queen's Medical Research Institute
2022
BackgroundMany repurposed drugs have progressed rapidly to Phase 2 and 3 trials in COVID19 without characterisation of Pharmacokinetics /Pharmacodynamics including safety data. One such drug is nafamostat mesylate.MethodsWe present the findings a phase Ib/IIa open label, platform randomised controlled trial intravenous hospitalised patients with confirmed COVID-19 pneumonitis. Patients were assigned randomly standard care (SoC), or an alternative therapy. Nafamostat was administered as...
High circulating galectin-3 is associated with poor outcomes in patients coronavirus disease (COVID-19). We hypothesized that GB0139, a potent inhaled thiodigalactoside inhibitor antiinflammatory and antifibrotic actions, would be safely effectively delivered COVID-19 pneumonitis.
Rationale: Galectin-3 (Gal-3) drives fibrosis during chronic lung injury, however, its role in acute injury (ALI) remains unknown. Effective pharmacological therapies available for ALI are limited; identifying novel concepts treatment is essential. GB0139 a Gal-3 inhibitor currently under clinical investigation the of idiopathic pulmonary fibrosis. We investigate and evaluate whether inhibition with offers protective role. The effect on was explored vivo vitro.Methods: pharmacokinetic...
ABSTRACT Despite the success of vaccines and selected repurposed treatments, COVID-19 is likely to remain a global health problem further chemotherapeutics are required. Many drugs have progressed rapidly Phase 2 3 trials without characterisation Pharmacokinetics (PK)/Pharmacodynamics (PD) including safety in COVID-19. One such drug Nafamostat Mesylate (Nafamostat), synthetic serine protease inhibitor with anticoagulant anti-inflammatory properties. Preclinical data has demonstrated that it...
Background: Many repurposed drugs have progressed rapidly to Phase 2 and 3 trials in COVID19 without characterisation of Pharmacokinetics /Pharmacodynamics including safety data. One such drug is Nafamostat Mesylate.Methods: We present the findings a phase Ib/II open label, platform randomised controlled trial intravenous hospitalised patients with confirmed COVID-19 pneumonitis. Patients were assigned randomly standard care (SoC), or an alternative therapy. was administered as infusion at...
Numerous circulating molecular biomarkers, including MMP1, MMP7 and VEGF have been described in patients with emphysema idiopathic pulmonary fibrosis (IPF). Fibrotic interstitial pneumonias IPF often co-exist emphysema. We sought to determine if these biomarkers can distinguish from very early fibrotic lung disease. Subjects for this retrospective cohort study were identified an existing local database biobank (ELFMEN, NCT04016181). High Resolution Computerised Tomography (HRCT) diagnosis of...